Verrica Pharmaceuticals downgraded by RBC Capital Mkts
$VRCA
Biotechnology: Pharmaceutical Preparations
Health Care
RBC Capital Mkts downgraded Verrica Pharmaceuticals from Outperform to Sector Perform
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/6/2024 | Buy → Neutral | H.C. Wainwright | |
| 11/5/2024 | Outperform → Sector Perform | RBC Capital Mkts | |
| 7/25/2023 | $10.00 | Hold → Buy | Needham |
| 3/22/2023 | $10.00 | Buy | Jefferies |
| 2/13/2023 | $4.00 → $11.00 | Sector Perform → Outperform | RBC Capital Mkts |
| 5/25/2022 | $16.00 → $4.00 | Outperform → Sector Perform | RBC Capital Mkts |
| 3/10/2022 | $20.00 | Buy | Brookline Capital |
| 3/3/2022 | $20.00 → $18.00 | Buy | Needham |
Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the settlement of litigation with Dormer Laboratories, Inc. ("Dormer Labs"). As part of the settlement, Dormer Labs has discontinued the sale of all cantharidin-containing products into the United States, including Dormer brands Cantharone (Liquid) and Cantharone Plus.
Needham analyst Serge Belanger reiterates Verrica Pharmaceuticals (NASDAQ:VRCA) with a Buy and maintains $16 price target.
4 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)
3 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)
4 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)
8-K - Verrica Pharmaceuticals Inc. (0001660334) (Filer)
424B5 - Verrica Pharmaceuticals Inc. (0001660334) (Filer)
8-K - Verrica Pharmaceuticals Inc. (0001660334) (Filer)
- Reports YCANTH® revenue, net of $4.9M for second quarter of 2024 along with the expansion of YCANTH's distribution footprint to include Cencora, Inc. as a specialty distributor – - Announces positive preliminary topline results of Phase 2 clinical study of VP-315 for the treatment of patients with basal cell carcinoma – - Continues to progress preparation for global Phase 3 Common Warts trial with initiation expected in 1H 2025 – - Conference Call Scheduled for Today at 8:30 am ET – WEST CHESTER, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical i
WEST CHESTER, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, August 14, 2024, to discuss the Company's financial results for the second quarter ended June 30, 2024, and provide an overview of topline results from Part 2 of the Phase 2 trial of VP-315 for the treatment of basal cell carcinoma. Individuals may participate in the live call via telephone by dialing 1-800-579-2543 (domestic) or 1-785-424-1789 (international)
– Reports YCANTH® revenue of $3.2M for first quarter of 2024 – – Over 228 million lives now covered to date on commercial insurance, managed Medicaid, Tricare and Federal Employee plans – – Preliminary Phase 2 results for VP-315 in the treatment of basal cell carcinoma (BCC) expected in the second quarter of 2024 – – Conference Call Scheduled for Today at 8:30 am ET – WEST CHESTER, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the first quarter ended March 31, 2024. "The first quarter of 2024
SC 13G/A - Verrica Pharmaceuticals Inc. (0001660334) (Subject)
SC 13G/A - Verrica Pharmaceuticals Inc. (0001660334) (Subject)
SC 13G - Verrica Pharmaceuticals Inc. (0001660334) (Subject)
– Company reported $0 in product shipments in the third quarter of 2024 and recognized negative net product revenue of $1.9 million, including a provision for product returns of $1.7 million– – Company expects existing distributor inventory to support most demand for dispensed applicator units into the first quarter of 2025 – – Company continues to look for ways to manage expenses and expand access to YCANTH® for the treatment of molluscum contagiosum – – Company announces new senior leadership with appointments of Dr. Jayson Rieger as Chief Executive Officer and John Kirby as Interim Chi
WEST CHESTER, Pa., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the second quarter ended June 30, 2021. "This quarter, we continued to ramp up commercial preparations for the potential FDA approval of VP-102, our lead product candidate for the treatment of molluscum contagiosum, including strengthening our senior leadership team and ensuring patient access to VP-102 through productive dialogue with medical providers and payors," said Ted White, Verrica's President and Chief Executive Officer. "With a
Company strengthens management team in anticipation of the potential commercial launch of VP-102, if approved WEST CHESTER, Pa., July 09, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the appointment of Terry Kohler as Chief Financial Officer. Mr. Kohler is a strategic and operational finance leader with over 20 years of commercial business experience, most recently at a global pharmaceutical company with annual revenues over $2 billion. Mr. Kohler is replacing Brian Davis, who is leaving Verrica to pursue other opportunities. "Te
H.C. Wainwright downgraded Verrica Pharmaceuticals from Buy to Neutral
RBC Capital Mkts downgraded Verrica Pharmaceuticals from Outperform to Sector Perform
Needham upgraded Verrica Pharmaceuticals from Hold to Buy and set a new price target of $10.00
Submission status for VERRICA PHARMACEUTICALS INC's drug YCANTH (ORIG-1) with active ingredient CANTHARIDIN has changed to 'Approval' on 07/21/2023. Application Category: NDA, Application Number: 212905, Application Classification: Type 5 - New Formulation or New Manufacturer
4 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)
4 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)
4 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)
WEST CHESTER, Pa., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the pricing of an underwritten public offering of 44,964,045 shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase 2,235,955 shares of its common stock, and in either case, accompanying Series A warrants to purchase 23,600,000 shares of its common stock at an exercise price of $1.0680 per share of common stock and Series B warrants to purchase 23,600,000 shares of its commo
WEST CHESTER, Pa., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it intends to offer and sell shares of its common stock (or pre-funded warrants to purchase its common stock in lieu thereof) and in either case, accompanying warrants to purchase shares of its common stock, in an underwritten public offering. All of the securities in the proposed offering will be sold by Verrica. Verrica intends to grant the underwriter a 30-day option to purchase additional shares of its common stock and/or accompanying
– Company reported $0 in product shipments in the third quarter of 2024 and recognized negative net product revenue of $1.9 million, including a provision for product returns of $1.7 million– – Company expects existing distributor inventory to support most demand for dispensed applicator units into the first quarter of 2025 – – Company continues to look for ways to manage expenses and expand access to YCANTH® for the treatment of molluscum contagiosum – – Company announces new senior leadership with appointments of Dr. Jayson Rieger as Chief Executive Officer and John Kirby as Interim Chi